Ioversol

Summary

Ioversol (CHEMBL1200614) is an approved small molecule (ATC V08AB07).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V08AB07
• Clinical trials: 5
• Chemistry: 807.1 Da · C18H24I3N3O9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200614
Name	Ioversol
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	3741
ATC	V08AB07
Molecular formula	C18H24I3N3O9
Molecular weight	807.1
InChIKey	AMDBBAQNWSUWGN-UHFFFAOYSA-N

SMILES: C(CO)N(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)CO

IUPAC name: 1-N,3-N-bis(2,3-dihydroxypropyl)-5-[(2-hydroxyacetyl)-(2-hydroxyethyl)amino]-2,4,6-triiodobenzene-1,3-dicarboxamide

Also known as: Ioversol, MP 328, MP-328, Optiray, Optiray 160, Optiray 240, Optiray 300, Optiray 320, Optiray 350, Ioversal, IOVERSOL, ioversol

Patent coverage: 1,761 distinct patent families (5,691 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE4	3
EARLY_PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00335101	PHASE4	WITHDRAWN	Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography
NCT00793182	PHASE4	TERMINATED	Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography
NCT03631771	PHASE4	WITHDRAWN	Pediatric Risk of Hypothyroidism With Iodinated Contrast Media
NCT02117115	EARLY_PHASE1	COMPLETED	Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
NCT07391787	Not specified	COMPLETED	Low-acid Contrast Media for Preventing Post ERCP Pancreatitis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).